🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

39 results for “Essential” Clear

  1. 60 mg ulixacaltamide

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 3 small molecule active

    1 trial

  2. ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  3. Amlodipine

    China SXT Pharmaceuticals

    Essential Hypertension

    phase 3 small molecule active

    1 trial

  4. Anagrelide Hydrochloride

    Takeda Pharmaceuticals International AG

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  5. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    4 trials

  6. Azilsartan medoxomil/placebo

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  7. CPI-0610, CPI-0610

    Novartis Ophthalmics Europe

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  8. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  9. DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -

    Celgene Europe Limited

    Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis

    phase 3 small molecule active

    1 trial

  10. MK-3543, HYDROXYCARBAMIDE , Placebo for hydroxycarbamide, MK-3543, MK-3543, MK-3543, Placebo for Bomedemstat

    Merck Sharp and Dohme

    Essential thrombocythemia

    phase 3 small molecule active

    1 trial

  11. MK-3543, MK-3543, MK-3543, MK-3543

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

  12. SPD422 (anagrelide hydrochloride)

    Takeda Pharmaceuticals International AG

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  13. TAK-536CCB

    Takeda Pharmaceuticals International AG

    Grade I or II Essential Hypertension

    phase 3 small molecule completed

    1 trial

  14. TAK-536TCH tablet

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  15. 10 mg PRAX-114, 20 mg PRAX-114, and Placebo

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule terminated

    1 trial

  16. 100 mg PRAX-944

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  17. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  18. Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

    GlaxoSmithKline Biologicals S.A.

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  19. JZP385

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  20. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Essential Thrombocythemia

    phase 2 small molecule terminated

    1 trial

  21. Matches test product

    Bioprojet Pharma

    Essential tremor

    phase 2 small molecule active

    1 trial

  22. NBI-827104

    NEUROCRINE BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  23. Part A: 20 and 40 mg PRAX-944

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  24. Placebo

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources